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β-thalassemia (βT) is a genetic blood disorder causing profound and life threatening anemia. Current 
clinical management of βT is a lifelong dependence on regular blood transfusions, a consequence 
of which is systemic iron overload leading to acute heart failure. Recent developments in gene and 
chelation therapy give hope of better prognosis for patients, but successful translation to clinical 
practice is hindered by the lack of thorough preclinical testing using representative animal models 
and clinically relevant quantitative biomarkers. Here we demonstrate a quantitative and non-invasive 
preclinical Magnetic Resonance Imaging (MRI) platform for the assessment of βT in the γβ0/γβA 
humanized mouse model of βT. Changes in the quantitative MRI relaxation times as well as severe 
splenomegaly were observed in the heart, liver and spleen in βT. These data showed high sensitivity 
to iron overload and a strong relationship between quantitative MRI relaxation times and hepatic iron 
content. Importantly these changes preceded the onset of iron overload cardiomyopathy, providing an 
early biomarker of disease progression. This work demonstrates that multiparametric MRI is a powerful 
tool for the assessment of preclinical βT, providing sensitive and quantitative monitoring of tissue iron 
sequestration and cardiac dysfunction- parameters essential for the preclinical development of new 
therapeutics.
β -thalassemia is an inherited blood disorder that causes the production of abnormal and ineffective red blood 
cells leading to profound and life threatening anemia. β -thalassemia patients present severely reduced synthesis 
of the beta globin chain component of adult hemoglobin, the resulting α - and β -globin chain imbalance leads 
to ineffective erythropoiesis1,2. The most severe form of this condition is β -thalassemia major (β TM) in which 
β -globin production is totally absent. Current clinical management of disease is a lifelong dependence on regular 
blood transfusions, a consequence of which is systematic cardiac iron overload leading to acute heart failure. At 
birth β T patients survive on fetal hemoglobin (HbF) and do not present symptoms until completing the transi-
tion to adult hemoglobin (HbA) at around 6 months of age. Survival into adulthood is then dependent on regular 
blood transfusions3,4. A consequence of repeated transfusions is the accumulation of iron due to the lack of any 
innate iron excretion mechanism and pathological transferrin saturation. Transfusion induced iron accumulation 
is compounded by increased gastrointestinal iron absorption as a result of hepcidin suppression associated with 
ineffective erythropoiesis5. If left untreated, iron accumulation leads to tissue iron overload and acute heart failure 
as a result of cardiac siderosis. Myocardial iron removal is slow with existing chelation regimens and the develop-
ment of more effective therapies and curative approaches is limited by the paucity of relevant animal models in 
which testing of new treatments can be investigated6–8.
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Mouse models for β T have been produced by deletion of the mouse β -globin genes, however in the absence 
of β -globin expression these mice die in utero making them unsuitable for serial studies2,9–12. Since mice have 
no equivalent of human HbF, these models do not express the characteristic transition from HbF to HbA seen 
in humans. Recent work by Huo et al. have developed humanized mouse models of β T that closely mimic the 
temporal fetal-to-adult hemoglobin switch and onset of anemia seen in humans with β T13–16. With the advent of 
representative animal models there is an urgent need for accurate non-invasive methods able to detect and quan-
tify iron load so that new therapies can be directly assessed in vivo.
The use of clinical magnetic resonance imaging (MRI) to assess the extent of iron loading in organs has rev-
olutionized the diagnosis, management and treatment of β T patients17–20. MRI has two primary advantages over 
other imaging or invasive diagnostic techniques; accurate measurement of cardiac structure and function; and 
direct quantification of iron loading due to shortening of magnetic relaxation times T1, T2 and T2* in the pres-
ence of iron. These properties make it the ideal tool for clinical monitoring of β T patients providing noninvasive 
monitoring of cardiac iron deposition and the consequential iron induced cardiomyopathy. Although MRI in 
thalassemia has become clinical practice where available, translation of quantitative MRI techniques to preclinical 
mouse models is challenging. Challenges to quantitative MRI include the rapid murine heart rate, approximately 
600bpm and small myocardium that is typically just 1mm thick. The consequence is that in vivo murine studies 
implementing quantitative relaxometry of T2, T2* and T1 values in the myocardium have been limited especially 
in the case of T2 and T2* measurements that are more susceptible to cardiac motion21–26.
This study developed clinically relevant MRI assessment methods to the novel humanized γ β 0 knockin mouse 
model of β -thalassemia in the presence of iron overload, for the first time. Tissue magnetic resonance relaxation 
rates (T1/T2/T2*), spleen volumetrics and cardiac function were quantified and demonstrates the utility of pre-
clinical MRI assessment in small animal models of thalassemia as an enabler to in-vivo and non-invasive serial 
investigation for the development of new therapies.
Materials and Methods
Animal models. All animal studies were approved by the University College London Biological Services 
Ethical Review Committee and licensed under the UK Home Office regulations and the Guidance for the 
Operation of Animals (Scientific Procedures) Act 1986 (Home Office, London, United Kingdom). All animal 
methods were performed in accordance to institutional ethical guidelines and regulations. The mouse models 
of β T were created by replacing the adult mouse α - and β -globin genes with human α -globin and human γ - to 
β -globin hemoglobin switching cassette (γ β 0 or γ β A). Homozygous fully humanized knockin (γ β 0/γ β 0) mice sur-
vive to birth by synthesizing solely human HbF and are an accurate model of β TM. Heterozygous fully human-
ized knockin (γ β 0/γ β A) mice show typical symptoms of β -thalassemia following completion of the fetal-to-adult 
hemoglobin switch including splenomegaly and mild anemia despite considerable changes in red blood cell 
(RBC) indices. Mice homozygous for the γ β A knockin (γ β A/γ β A) survived into adulthood by synthesizing human 
HbA, this model acted as a wild type control to account for the presence of the human globin genes. Three groups 
of animals were studied:
Humanized Control: Humanized γ β A/γ β A control mice (n = 7).
Control Thalassemia: Heterozygous knockin γ β 0/γ β A β -thalassemia mice (n = 6).
Iron-loaded Thalassemia: 
Heterozygous knockin γ β 0/γ β A β -thalassemia mice (n = 6) received 
daily intraperitoneal injections of 10 mg iron dextran in 100 μ L PBS 
for 4 weeks (5 days/week) to simulate iron loading resulting from 
repeated blood transfusions.
Humanized control and control thalassemia mice received injections of PBS with the same regimen. All injec-
tions began at 4 Months of age.
In vivo MRI. Imaging was performed at 5 months of age using a 9.4 T MRI system (Agilent Technologies, 
Santa Clara, USA) equipped with 1000mT/m gradient inserts and a 39mm volume resonator RF coil (RAPID 
Biomedical, Rimpar, Germany). A small animal physiological monitoring system (SA Instruments, Stony Brook, 
NY) was used to maintain depth of anesthesia and animal physiology. The ECG trace was recorded using 3-lead 
subcutaneous electrodes, respiration rate was measured by a pressure sensitive balloon and internal temperature 
by rectal thermometer. Animals were anesthetized under a mixture of 1–2% isoflurane in oxygen.
Spleen volume. Spleen volume data were acquired in control and non-loaded thalassemia mice using a 
respiration gated multislice gradient echo axial sequence (GEMS) with in-plane resolution 156 μ m/px, slice thick-
ness 0.5 mm, flip angle 20°, TE 3.2 ms. In iron loaded mice due to ultra-short T2/T2* relaxation in the spleen a 
GEMS protocol was impractical, in this case a respiration gated T1-weighted spin-echo multislice sequence was 
used with in-plane resolution 234 μ m, slice thickness 1 mm, TE 2.5 ms, TR 600 ms. In both cases the number of 
slices was adapted to the cover the whole spleen volume. Image data was reconstructed offline and spleen tissue 
was identified by drawing organ contours on individual 2D slices and propagating through plane to measure 
organ volume. The ratio of spleen volume to total animal mass was used as a quantitative and animal-independent 
value for spleen size.
Relaxometry. Transverse relaxation mechanisms T2 and T2* are the time constants describing the rate 
of transverse MRI signal decay and depend on the microscopic magnetic environment of tissue. The large 
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paramagnetic influence of iron storage molecules ferritin and hemosiderin cause perturbations to the magnetic 
environment. This results in faster transverse relaxation proportional to the concentration iron species, making 
T2/T2* quantifiable markers for iron-overload27,28.
T2 relaxation was measured using a cardiac and respiratory gated spin echo sequence where a respiratory gate 
triggered acquisition of one phase encoding line per slice per R-wave until the next respiration. This acquisition 
was repeated at 8 echo times ranging from 2.7–20 ms. Typical respiration and heart rates allowed for 7 slices with 
0.3 × 0.3 × 1.5mm/px resolution covering 6 slices in the heart and liver with one through the spleen. The T2 signal 
relaxation could then be fitted to a model of transverse signal decay: = +−S TE S e C( ) TE T0
/ 2  where TE is echo 
time, S0 is the initial signal intensity and C is a fitted offset to account for image noise.
T2* relaxation was then measured using two multi gradient echo sequences with 15 echo times in the range of 
0.9–14.9 ms at 1ms intervals. These images had a 0.23 × 0.23 × 1.5 mm/px resolution. One slice was placed in the 
same orientation as the T1 look locker and second acquisition was orientated in the spleen. The signal intensities 
were then modelled as T2* relaxation using according to the same model as T2 with T2* substituted for T2. Both 
T2 and T2* are shortened in the presence of iron, however T2* can be effected by other magnetic susceptibility 
induced field changes in particular the effect of the air filled lung cavity can artificially shorten T2* in the heart. 
To limit this effect all cardiac T2* measurements used only the intraseptal region where the magnetic field is most 
uniform.
To measure T1 relaxation a cardiac gated look locker sequence was used with a minimum TE of 2.8 ms fol-
lowed by 30 inversion times separated by the RR interval29. The slice was orientated so as to cover the 
mid-papillary level short axis of the heart and a portion of liver allowing for both tissues to be quantified during 
a single scan with an in-plane resolution of 0.3 mm/px and a slice thickness of 1.5 mm. This resulted in an image 
sequence where signal intensity could be modelled by a 3 component model = − +− ∗S TI S Be C( ) (1 )TI T0
/ 1 , 
where TI is the time following the radiofrequency look locker inversion pulse, B is a fitted parameter to account 
for imperfect inversion and T1* is the apparent T1 under the influence of look locker saturation. This is corrected 
by the correction factor = −T B T1 ( 1) 1*. Due to the long sampling time for T1 decay the acquisition was 
acquired over respirations, images corrupted with respiration motion were automatically excluded from fitting 
using the phase-encoded noise-based image rejection scheme30.
Tissue regions were segmented and models fitted to mean ROI values at each echo time. Model fitting was 
performed using in house Matlab optimization code (2014b, The Mathworks, Inc., Natick, USA) based on the 
Nelder-Mead Simplex Method.
Cardiac function. Cardiac function was assessed with a spoiled gradient echo cine MRI sequence with a 
temporal resolution of 5 ms where the number of cine frames was matched to cover the complete cardiac cycle. 
The acquisition used an in plane spatial resolution of 117 μ m/px and a slice thickness of 1 mm. The left ventricular 
blood pool was segmented at systole and diastole using Segment v1.8 R046231 and the corresponding volumes 
used to calculate left ventricular ejection fraction (EF), stroke volume (SV) and end systolic/diastolic volumes 
(ESV/EDV)32.
Iron quantification and histology. Following imaging animals were sacrificed and samples of heart, 
spleen and liver were fixed in 4% PFA for analysis. Non-heme tissue iron concentration was measured using the 
iron assay described by Bothwell et al.33 and iron deposits were observed histologically by Perls’ stain.
Statistical tests. All results are presented as mean value ± standard error. All data were tested for normal-
ity using the Kolmogorov-Smirnov test and significance values were calculated by one-way analysis of variance 
corrected for multiple comparisons using the Holm-Šídák method. In all cases a p-value of less than 0.05 was 
considered significant.
Results
T2/T2* relaxation. Measurements of cardiac, hepatic and splenic T2 and T2* are shown in Fig. 1 and Fig. 2 
respectively, along with representative images from each group at identical echo times for comparison.
Myocardial T2 was greatly shortened in iron-loaded thalassemia mice (3.3 ± 0.3 ms) versus humanized 
controls (18.0 ± 0.8 ms) and thalassemia controls (17.2 ± 2.1 ms). Similarly, myocardial T2* in iron over-
load (0.7 ± 0.2 ms) was shortened relative to humanized controls (11.5 ± 4.3 ms) and thalassemia controls 
(10.1 ± 5.2 ms). These data show that T2 and T2* show detectable sensitivity to iron loading in this animal model. 
There was no significant difference in T2 or T2* between the non-iron loaded groups indicating that the addi-
tional iron uptake in the heterozygous humanized γ β 0/γ β A model is not severe enough in itself to produce a 
detectable change in cardiac T2 or T2* at 5 months of age.
Hepatic T2 was shortened in both the control thalassemia (9.4 ± 2.9 ms) and iron-loaded thalassemia mice 
(1.3 ± 0.3 ms) relative to humanized controls (13.2 ± 01.0 ms). Similarly, hepatic T2* was shortened in the control 
thalassemia (4.7 ± 1.5 ms) and iron-loaded thalassemia mice (0.6 ± 0.2 ms) models relative to humanized controls 
(7.6 ± 1.9 ms). This shortening of T2 and T2* in both the thalassemia groups can be related to the role of the liver 
as the primary reserve for body iron stored as ferritin. In the thalassemia control group increased dietary iron 
uptake could explain this shortening while in the iron-loaded thalassemia group we see this effect exaggerated by 
the additional exogenous iron deposition.
The role of the spleen in breaking down senescent erythrocytes makes it hyperactive in thalassemia where 
a large population of erythrocytes are defective. Splenic iron deposition is primarily due to the break-down of 
erythrocytes and hemoglobin in the spleen. The heme by-product is transported to the liver by transferrin which 
in thalassemia can become saturated preventing removal. The shortened T2 and T2* in both thalassemia groups 
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reflects this process. Splenic T2 was shortened in control thalassemia mice (3.9 ± 0.8 ms) and iron-loaded thalas-
semia (1.7 ± 0.9 ms) compared with humanized controls (6.2 ± 0.8 ms). Splenic T2* was further shortened in iron 
overload mice (0.8 ± 0.1 ms) and control thalassemia (0.6 ± 0.5 ms) relative to humanized controls (1.5 ± 0.3 ms).
It is known that iron accumulation occurs initially in the macrophage system of the spleen, liver and bone 
marrow but subsequently in hepatocytes and ultimately in the heart and endocrine systems. These MRI meas-
urements show that at 5 months of age the liver and spleen show signs of iron loading but the process has not yet 
begun to accumulate iron in the heart suggesting that this is a relatively early stage of disease.
T1 relaxation. T1 values were significantly shorter in the presence of iron loading (Fig. 3). Cardiac T1 was 
shorter in iron-loaded mice (620 ± 125 ms) relative to control thalassemia mice (1041 ± 261 ms) and human-
ized control animals (928 ± 115 ms). This was also the case for hepatic T1, with iron loaded thalassemia ani-
mals having shorter T1 (456 ± 85 ms) than control thalassemia (1014 ± 255 ms) and humanized control animals 
(929 ± 117 ms). These data show that T1 is sensitive to the presence of iron loading however, T1 changes in the pres-
ence of iron require direct interaction with ferritin or hemosiderin, the sensitivity is therefore lower than T2/T2*. 
T1 measurements could therefore be useful at particularly high iron concentrations where T2/T2* can be too 
short to accurately quantify.
Spleen volume. A severe increase in spleen size was observed in the presence of the γ β 0 gene. Figure 4 
shows a comparison of the axial spleen images and highlights the enlarged spleens in iron loaded and control 
thalassemia mice. Spleen volume normalized to body mass was significantly increased in control thalassemia 
(9.5 ± 1.2 mm3/g) and iron loaded thalassemia mice (9.1 ± 1.3 mm3/g) relative to humanized control mice 
(4.0 ± 0.4 mm3/g), however there was no significant change in volume between iron loaded and control thalas-
semia mice suggesting that splenomegaly in this animal model is a purely a consequence of γ β 0 knockin and is not 
directly affected by the degree of iron deposition.
Cardiac function. Quantitative values describing left ventricular function are shown in Fig. 5. Left ventricu-
lar end diastolic, end systolic and stroke volumes (SV) were preserved between groups. Cardiac output (CO), 
measured as the product of stroke volume and heart rate was not significantly altered in control thalassemia mice 
(14.1 ± 2.1 ml/min) relative to humanized controls (15.6 ± 1.1 ml/min) and iron-loaded mice (12.4 ± 1.5 ml/min) 
indicating that at 5 months of age that the two heterozygous knockin groups have not developed the pathological 
high output state characteristic of anemia. Left ventricular EF was also unchanged in iron-loaded mice (70 ± 2%) 
relative to control thalassemia mice (57 ± 4%) and humanized control animals (65 ± 2%).
Figure 1. T2 relaxation times in the heart, liver and spleen with representative images at TE = 5 ms. T2 
was shortened in the liver and spleen for the control thalassemia animals and more severely shortened in the 
case of iron-loaded thalassemia mice. Cardiac T2 was shortened in the iron loaded thalassemia mice but not 
the control thalassemia animals. Representative images depict oblique slices showing the cardiac short axis and 
liver, in iron loaded animals the liver shows severe signal hypointesity and there is a visibly progressing drop in 
signal between images matching the T2 measurements. (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 2. T2* relaxation times in the heart, liver and spleen with representative images at TE = 1.8ms. 
T2* relaxation was shortest in the iron-loaded thalassemia animals in the heart, spleen and liver. The hepatic 
T2* of the control thalassemia mice also showed a significant (p = 0.0042) reduction. Cardiac T2* showed the 
same trend as T2 with no significant change between control and thalassemia controls. (*p < 0.05, **p < 0.01, 
***p < 0.001).
Figure 3. T1 relaxation times in the heart, liver and spleen with representative images at TI = 110ms. 
T1 relaxation in heart and liver was significantly shortened relative to controls in iron-loaded thalassemia 
mice (p = 0.0455 and p = 0.0009 respectively). In both the liver and spleen but not significantly effected in the 
thalassemia control mice. (*p < 0.05, ***p < 0.001).
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Histology. Histological sections of spleen, heart and liver are shown in Fig. 6A. Small iron deposits are visible 
by blue/purple staining in the liver and spleen of the thalassemia control group but there are no iron deposits vis-
ible in cardiomyocytes. This iron distribution is consistent with early stage iron overload where the iron has not 
spread beyond the macrophage system in the liver and spleen. In the iron loaded thalassemia group there are large 
iron deposits in the liver and spleen but crucially iron deposits are now visible in the myocardium. Iron concen-
tration determined by the Bothwell non-heme assay for each organ and group is shown in Fig. 6B. Control thalas-
semia hearts did not show significantly higher iron content than humanized controls but iron loaded thalassemia 
animals showed large myocardial iron depositions. Hepatic iron content was higher than humanized controls in 
control thalassemia and iron-loaded animals while splenic iron showed an increasing trend but the results did 
not reach statistical significance. These results match the T2/T2* relaxometry measurements verifying these data.
Iron calibration. The cardiac T2* and iron dry weight measurements can be used to create a calibration curve 
to estimate iron content of dry tissue. This relationship can be modeled as = −⁎ ⁎Fe T T K[ ] (1/ 2 1/ 2 )/dry dry0  where 
T2* is the measured T2* value, T20* is the T2* of the heart in the absence of iron loading and Kdry is a proportion-
ality constant for dry tissue24. Here we take the mean T2* of humanized controls as T20* and fitted Kdry to the 
measured T2* and dry iron concentrations. The resulting calibration curve fits measured values well (Fig. 7) and 
shows a sharp increase in estimated tissue iron at T2* < 2 ms. The process can be repeated for T2 measurements 
by substituting T2 for T2*. In this case we find that iron concentration increases sharply at T2 < 5 ms.
Discussion
In humans T2* MRI is the primary technique for identifying pathological iron overload in β T and has revolution-
ized the early diagnosis of disease prompting leaps in life expectancy as MRI becomes more readily available1. A 
myocardial T2* of < 10 ms is the recognized primary predictor of iron induced heart failure in patients with iron 
overload. In this study we find a similar rapid increase in estimated cardiac iron content at < 2 ms. The T2 and T2* 
calibration curves fitted in Fig. 7 are representative of calibration curves seen in humans. This similar pattern is 
a promising sign that the animal model is clinically representative and that serial measurements of tissue iron by 
MRI can establish trends in tissue iron loading during the onset and following the treatment of β T, enabling more 
clinically useful interpretation of efficacy of such treatments.
Figure 4. Representative images showing the enlargement of the spleen in thalassemia. Spleens (S) were 
dramatically enlarged relative to humanized controls in control and iron-loaded thalassemia mice. The 
spleen can be identified in MRI images by its speckled texture due to the dense trabeculae. Spleen volume was 
quantified by the ratio of spleen volume to animal mass. (**p < 0.01).
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The small organ size of rodents necessitates the use of high field MR imaging systems to obtain adequate 
temporal and spatial resolution and brings major challenges to imaging due to shortened relaxation times and 
accentuated field inhomogeneity. T2* is currently the clinical standard for assessment of iron overload and has 
been universally adopted, however T2* is influenced by a number of factors independent of tissue iron concen-
tration. The dense capillary networks within the myocardium have a significant impact on cardiac T2* relaxation 
due to their tortuous geometry and magnetic susceptibility which can be altered in disease. In β T blood of var-
ying degrees of oxygenation can drastically alter relaxation rates due to the different magnetic properties of oxy 
and deoxyhemoglobin. Variation in B0 shimming and long range susceptibility effects from the lungs can also 
influence measurements. Alternatively, T2 relaxation is less affected by these variations but has a lower sensitivity 
to iron. Here we found that T2 and T2* provide the same information with regards to iron concentration in the 
heart, liver and spleen. It is therefore feasible to use T2 as a more accurate quantitative measure of tissue iron when 
high sensitivity to iron is not required. T2 has also been shown to be a useful and reproducible measure of tissue 
iron in humans, however T2* remains the gold standard due to the substantial number of validation studies34,35.
The true relationship between myocardial iron and T2/T2* relaxation has previously proven difficult to deter-
mine. Although the shortening effect of iron is recognized it must be determined that iron is the dominant factor 
in faster transverse relaxation in β T as opposed to the abnormal hemodynamics. Iron concentration in this study 
was found to follow the same trend as T2 and T2* values for each organ. The control thalassemia and iron-loaded 
thalassemia groups have identical γ β 0/γ β A knockin genes and present the same variable blood oxygenation and 
myocardial capillary networks of β T. The iron-loaded animals demonstrated a shortening of T2 and T2* regard-
less of this providing evidence that the dominant T2/T2* shortening factor in β T is iron accumulation.
Pronounced splenomegaly was observed in the γ β 0 knockin mice irrespective of the presence of iron overload 
in the organ. This is consistent with the main cause of splenomegaly in β T being the extended tissue hypoxia 
with splenic siderosis playing a minor role in organ dysfunction. Since the spleen functions primarily as a filter 
Figure 5. Measurements of myocardial function from cine MRI. No significant changes in cardiac volumes 
were observed between groups, although the iron-loaded thalassemia animals had an elevated ejection fraction 
relative to control thalassemia mice. This suggests that iron induced cardiomyopathy has not yet developed 
suggesting MRI relaxometry could be a useful early biomarker for the onset of β T.
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to remove damaged RBCs it can become hyperactive in the case of β T due to the high population of defective 
RBCs36,37. Hypersplenism and splenomegaly shorten the lifetime of transfused RBCs creating a requirement for 
more frequent transfusions and compounding the consequential iron overload, therefore successful treatment 
of β T will require slowing or prevention of hypersplenism. In this study MRI has been shown to be a useful tool 
for assessing the extent of organ enlargement and the ability to serially measure this in vivo will be valuable for 
therapeutic development.
In anemic states the heart compensates for low blood oxygen content by increasing cardiac output to maintain 
tissue oxygenation, typically through increasing end diastolic volume38. Results here however do not show a signif-
icant increase of these cardiac metrics in γ β 0/γ β A knockin mice relative to humanized γ β A/γ β A controls. The likely 
explanation for this is the relatively mild anemia in the heterozygous γ β 0/γ β A knockin mice, meaning that com-
pensatory increases in cardiac output are not required. Although cardiac dysfunction is not observed, an increase 
in ferritin and hemosiderin from assay and relaxometry measurements is seen in iron loaded and thalassemia mice 
and is known to predispose a patient to cardiac dysfunction in the future due to the corresponding increase in 
toxic labile iron39. The onset of cardiac dysfunction in the presence of iron overload is well established and the data 
presented here suggests that relaxometry measurements and increased spleen volume precede the onset of cardiac 
dysfunction and can be used as early markers for the progression of disease and is the same in the clinical setting1.
Current research into therapies for β T typically focuses on either gene therapy, novel iron chelation agents or 
inducing post-natal production of HbF. Gene therapy approaches aim to modify harvested autologous hemopoietic 
Figure 6. Histological validation of iron concentrations in the heart, liver and spleen. Perls stain for iron 
(A) show iron deposits in the spleen, liver and heart. Iron accumulation in the heart only occurs following 
iron loading and not in control thalassemia mice. Results of the Bothwell iron assay (B) show that T2 and 
T2* measurements are good markers for iron content, significance relative to humanized controls (*p < 0.05, 
***p < 0.001). Iron content shows an inverse relationship with transverse relaxation mechanisms in the liver.
Figure 7. Calibration curves for myocardial dry iron concentration from cardiac T2 and T2* relaxation 
times. Creating a calibration curve between these two measurements allows estimations of cardiac iron content 
to be made without the use of an invasive cardiac iron assay. Points show individual animals, humanized 
controls (■ ), Thalassemia controls (▲ ) and iron-loaded thalassemia (• ), grey/black points correspond to the 
T2/T2* measurements respectively.
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stem cells in-vitro, repairing the dysfunctional β -globin genes before transplanting them back to the patient40. Gene 
therapy has been shown to be effective in mice for various forms of β -thalassemia41–44. These studies required ani-
mals to be culled at each time point to assess severity of disease, the in-vivo nature of MRI imaging means it would 
be a valuable addition to these studies providing a means to characterizing the time course of treatment. Iron chela-
tion therapy is a necessary accompaniment to regular blood transfusions. Currently there are just three common 
clinically approved iron chelators: Deferoxamine, Deferiprone and Deferasirox. Each drug has its relative adverse 
effects and challenges meaning that the development of new agents is an active field of research45. There are prom-
ising agents such as FBS0701 that has many advantageous properties relative to current chelators and is currently 
undergoing phase II clinical trials in which MRI assessment of iron concentration and cardiac function are primary 
endpoints46. FBS0701 has undergone preclinical assessment of toxicity and safety but these studies did not utilize 
MRI techniques which would have provided translatable information for clinical trials47,48. Future preclinical studies 
into the safety of new agents will greatly benefit from integrating the MRI assessments that we present here, allowing 
parallel investigation of toxicity and iron chelation efficacy serially in vivo.The data presented here demonstrates 
that MRI can be used to characterize the γ β 0 knockin mouse model of β T. Both spleen volumetrics and relaxometry 
distinguished between humanized controls, control thalassemia knockin mice and iron-loaded thalassemia mice 
with a marked increase in spleen volume and shortening of relaxation times in thalassemia mice. The increasing 
iron content in the thalassemia animals quantified by chemical iron assay and visualized by Perls’ stain (Fig. 6) 
confirms the inverse relationship between increasing iron load and decreased T2 and T2* relaxation time in tissue.
Conclusion
In this work we have presented the first study to use multiparametric quantitative MRI to assess tissue iron, 
spleen volume and cardiac function in the γ β 0 knockin mouse model of β -thalassemia. Measurements of T2/T2* 
show great potential as a specific and sensitive biomarker for preclinical monitoring of iron accumulation, while 
measurements of spleen volume and heart function are able to provide additional biomarkers to assess disease 
progression. Using MRI to quantify β T in experimental animal models will be a powerful tool to assist in the 
development of new therapies and is directly translatable to clinical practice.
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